| 8.99 0.6 (7.15%) | 02-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.42 | 1-year : | 13.34 |
| Resists | First : | 9.77 | Second : | 11.42 |
| Pivot price | 8.47 |
|||
| Supports | First : | 8.03 | Second : | 6.96 |
| MAs | MA(5) : | 9.06 |
MA(20) : | 8.31 |
| MA(100) : | 9.36 |
MA(250) : | 6.4 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 64.1 |
D(3) : | 75.5 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 12.34 | Low : | 2.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FDMT ] has closed below upper band by 29.1%. Bollinger Bands are 2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9 - 9.04 | 9.04 - 9.09 |
| Low: | 8.32 - 8.36 | 8.36 - 8.41 |
| Close: | 8.92 - 8.99 | 8.99 - 9.06 |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Mon, 02 Feb 2026
Barclays flags M&A tailwinds and pricing relief as upside catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - MSN
Mon, 02 Feb 2026
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - Yahoo Finance
Wed, 28 Jan 2026
Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga
Wed, 28 Jan 2026
Barclays Initiates Coverage of 4D Molecular Therapeutics (FDMT) with Overweight Recommendation - Nasdaq
Sat, 17 Jan 2026
Biotech 4DMT hands 23,600 stock units to four new hires under award plan - stocktitan.net
Sat, 27 Dec 2025
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -104 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.101e+007 (%) |
| Held by Institutions | 4.291e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7796e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.72 |
| Profit Margin | 0 % |
| Operating Margin | -65 % |
| Return on Assets (ttm) | 538.8 % |
| Return on Equity (ttm) | -27.7 % |
| Qtrly Rev. Growth | 120000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.227e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -2.43 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 9.48e+006 |
| Forward Dividend | 5.02e+006 |
| Dividend Yield | 105451000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|